By Dr Derek Jellinek
24 May 2022, 9:30 AM
Nothing too earth shattering was revealed at the inaugural strategy day, with Healius' (ASX:HLS) continued evolution to become a scaled, digitally-enabled diagnostic operator.
Read more...
By Dr Derek Jellinek
04 May 2022, 8:35 AM
While we continue to believe a full recovery from COVID-based disruptions still has time to play out, improving demand and strong pipeline, coupled with management's increasing confidence, is all suggestive of an improving earnings profile.
Read more...
By Iain Wilkie
17 March 2022, 11:00 AM
We have compiled a list of 75 ASX-listed micro to mid-cap healthcare/life science companies and highlight key catalysts expected to read out over the next 18 months.
Read more...
By Dr Derek Jellinek
24 February 2022, 1:30 PM
1H underlying results were above expectations, with solid revenue growth underpinned by COVID-related gains and cost outs, driving margins and OCF to record levels.
Read more...
By Dr Derek Jellinek
23 February 2022, 9:00 AM
Cochlear (ASX:COH) 1H results were better than expected, underpinned by strong sales growth, expanding GPM and OPM, and solid OCF (+44%).
Read more...
By Dr Derek Jellinek
22 February 2022, 9:00 AM
Sonic Healthcare's (ASX:SHL) 1H underlying results were in line with expectations, underpinned by COVID-19 testing, pushing OPM to highs and boosting OCF (+28%).
Read more...
By Dr Derek Jellinek
17 February 2022, 11:30 AM
CSL Ltd's (ASX:CLS) 1H results were better than expected, albeit in line with management’s assumptions, with net profit down 5% in cc on 4% revenue growth.
Read more...
By Iain Wilkie
17 February 2022, 11:00 AM
Pro Medicus (ASX:PME) delivered a strong result with NPAT up 52.7% to A$20.7m, above our forecasts and consensus.
Read more...
By Dr Derek Jellinek
16 February 2022, 11:30 AM
Ansell's (ASX:ANN) 1H22 was pre-released so devoid of major surprises, with underlying earnings -24%.
Read more...
By Dr Derek Jellinek
14 February 2022, 12:00 PM
We go over the key stocks we are looking out for in the Healthcare sector this February Reporting Season. Stocks include; ResMed Inc (ASX:RMD), Pro Medicus (ASX:PME), Healius (ASX:HLS), Virtus Health (ASX:VRT), Monash IVF (ASX:MVF), and CSL Ltd (ASX:CSL).
Read more...